|
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands
Correspondence: For correspondence or reprints contact: Ronald Boellaard, Department of Nuclear Medicine and PET Research, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. E-mail: r.boellaard{at}vumc.nl
Quantitative 18F-FDG PET is increasingly being recognized as an important tool for diagnosis, determination of prognosis, and response monitoring in oncology. However, PET quantification with, for example, standardized uptake values (SUVs) is affected by many technical and physiologic factors. As a result, some of the variations in the literature on SUV-based patient outcomes are explained by differences in 18F-FDG PET study methods. Various technical and clinical studies have been performed to understand the factors affecting PET quantification. On the basis of the results of those studies, several recommendations and guidelines have been proposed with the aims of improving the image quality and the quantitative accuracy of 18F-FDG PET studies. In this contribution, an overview of recommendations and guidelines for quantitative 18F-FDG PET studies in oncology is provided. Special attention is given to the rationale underlying certain recommendations and to some of the differences in various guidelines.
Key Words: guidelines standards PET standardized uptake value
COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.
This article has been cited by other articles:
![]() |
W. A. Weber Assessing Tumor Response to Therapy J. Nucl. Med., May 1, 2009; 50(Suppl_1): 1S - 10S. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |